-
-
CleanSpark closes $2.28 billion senior secured notes offering
-
Texas Pacific Land extends executive contracts and announces 2027 annual meeting date
-
Why is Circle Internet stock sliding today?
-
New York and New Jersey declare states of emergency, bracing for flooding and outages from nor’easter
-
Exclusive-OpenAI works to understand full scope of agent activity as user data leak emerges
-
New Jersey’s lieutenant governor resigns amid sexual harassment findings
-
Fortinet CFO Christiane Ohlgart sells $8,640 in company stock
-
Goldgroup Mining closes $122 million private placement
-
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but inescapable. Shortages have dominated news headlines, and singsong commercials about the best online GLP-1 programs have taken over airwaves. GLP-1s have gone so far as to…